GLP-1 Side Effects: What to Expect in Your First Months

Most people who start a GLP-1 receptor agonist will experience some gastrointestinal side effects, particularly during the first few weeks. Nausea is the single most common side effect, reported by roughly 20-44% of participants across major clinical trials, depending on the specific medication and dose. The good news is that these symptoms are generally mild to moderate, tend to peak during dose escalation, and typically improve as your body adjusts over the first two to three months. Understanding what to expect may help you stick with treatment through the adjustment period.

Common Gastrointestinal Side Effects

GLP-1 medications work in part by slowing gastric emptying, which helps you feel full longer but can also cause digestive discomfort. The most frequently reported GI side effects in clinical trials include:

Nausea is the most prevalent side effect across the class. In the STEP 1 trial of semaglutide 2.4 mg (Wegovy), approximately 44% of participants in the treatment group reported nausea, compared to 18% in the placebo group. In the SURMOUNT-1 trial of tirzepatide (Mounjaro/Zepbound), nausea rates ranged from 24% to 33% depending on dose. Most episodes were rated as mild to moderate.

Vomiting occurred in roughly 24% of participants taking semaglutide 2.4 mg in STEP 1, and in approximately 9-13% of tirzepatide participants in SURMOUNT-1. This side effect is more common during the initial titration weeks.

Diarrhea was reported in about 30% of the semaglutide group in STEP 1 and 18-23% across tirzepatide doses in SURMOUNT-1. Episodes generally decreased over time.

Constipation affected roughly 24% of participants on semaglutide 2.4 mg in STEP 1, and 11-17% on tirzepatide in SURMOUNT-1. Adequate hydration and fiber intake may help manage this symptom.

Other commonly reported effects include abdominal pain, bloating, dyspepsia (indigestion), and decreased appetite. While reduced appetite is part of the therapeutic effect, some people may find it more pronounced than expected during early treatment.

Why Titration Matters

GLP-1 medications use a gradual dose escalation schedule specifically to reduce the severity of side effects. For example, semaglutide (Ozempic) starts at 0.25 mg weekly for four weeks before increasing to 0.5 mg, and may eventually reach 1 mg or 2 mg. Tirzepatide (Mounjaro) starts at 2.5 mg and increases in steps over several months.

This titration approach allows your GI system to adjust to the medication gradually. According to prescribing information, most GI side effects are concentrated in the dose-escalation phase. In the SUSTAIN and STEP trial programs, the majority of nausea episodes occurred during the first 8-12 weeks and declined substantially thereafter.

If side effects are particularly bothersome during a dose increase, your prescriber may recommend staying at the current dose for a longer period before advancing. This is a common and medically appropriate strategy.

How Side Effects Typically Improve Over Time

Clinical trial data suggest a general pattern for GI side effects:

• Weeks 1-4: Side effects may begin within days of the first injection. Nausea is typically mild.
• Weeks 4-12: Symptoms may briefly intensify with each dose increase but generally become less frequent between escalations.
• Months 3-6: Most participants report significant improvement in GI symptoms. In the STEP program, the majority of nausea episodes were transient and resolved without treatment discontinuation.
• Beyond 6 months: The proportion of participants reporting ongoing GI issues is substantially lower than during the titration period.

Across the STEP and SURMOUNT trials, roughly 4-7% of participants discontinued treatment due to GI adverse events. This means the large majority were able to continue treatment as symptoms improved.

Serious but Rare Side Effects

While most side effects are GI-related and temporary, GLP-1 medications carry warnings about less common but potentially serious adverse events. These deserve awareness even though they affect a small minority of users.

Pancreatitis: Cases of acute pancreatitis have been reported with GLP-1 receptor agonists. In clinical trials, the incidence was low (generally less than 0.5%), but all FDA-approved GLP-1 medications include pancreatitis in their warnings and precautions. Symptoms to watch for include severe, persistent abdominal pain that may radiate to the back, sometimes accompanied by vomiting. If you experience these symptoms, contact your healthcare provider immediately.

Gallbladder events: Cholelithiasis (gallstones) and cholecystitis (gallbladder inflammation) have been reported at higher rates in GLP-1 clinical trials compared to placebo, particularly in weight management trials. In STEP 1, gallbladder-related events occurred in approximately 2.6% of semaglutide participants versus 1.2% on placebo. Rapid weight loss from any cause can increase gallstone risk.

Thyroid C-cell tumors (boxed warning): All GLP-1 receptor agonists carry an FDA boxed warning based on findings in rodent studies, where these medications caused thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). It is not known whether GLP-1 medications cause thyroid C-cell tumors in humans. These medications are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Kidney injury: There have been postmarketing reports of acute kidney injury in patients taking GLP-1 receptor agonists, sometimes associated with dehydration from severe nausea, vomiting, or diarrhea. Maintaining adequate hydration is important, particularly during dose escalation.

Practical Tips for Managing Side Effects

The following strategies may help reduce GI discomfort, though individual responses vary:

• Eat smaller, more frequent meals rather than large portions. A full stomach combined with slowed gastric emptying can worsen nausea.
• Avoid high-fat and greasy foods, especially during the first weeks. These foods take longer to digest and may intensify symptoms.
• Stay hydrated. Sipping water throughout the day may help with both nausea and constipation.
• Eat slowly and stop when you feel satisfied. GLP-1 medications amplify fullness signals, and overeating can lead to significant discomfort.
• Consider the timing of your injection. Some people find that taking their weekly injection in the evening or before a less active day helps them manage any next-day nausea.
• Increase fiber gradually if constipation is an issue, and discuss over-the-counter options with your pharmacist.
• Keep a symptom log to share with your prescriber, especially during dose changes.

When to Contact Your Healthcare Provider

You should reach out to your doctor if you experience severe or persistent vomiting, signs of dehydration, severe abdominal pain, symptoms of an allergic reaction (rash, swelling, difficulty breathing), or any side effect that significantly affects your daily life. Your prescriber can help determine whether adjusting the dose, extending the titration schedule, or switching to a different medication is appropriate.

For more detailed comparisons of how specific medications differ in their side effect profiles, see Mounjaro vs Ozempic, Ozempic vs Wegovy, or browse all medications.

Talk to Your Doctor

This article is for informational purposes only and does not constitute medical advice. Side effect experiences are highly individual, and clinical trial data represent averages across large populations. Before starting, stopping, or changing any GLP-1 medication, discuss your full medical history, current medications, and personal risk factors with your healthcare provider. Your doctor can help you weigh the potential benefits against the risks and develop a plan that is right for your situation.